| Compatibility of Recombinant Tissue Plasminogen Activator and Bevacizumab Co-Applied for Neovascular Age-Related Macular Degeneration With Submacular Hemorrhage. | |
| | |
MedLine Citation:
|
PMID: 22410628 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
OBJECTIVE: To investigate the compatibility of recombinant tissue plasminogen activator (rtPA) and bevacizumab in vitro because during surgery, rtPA or rtPA-induced plasmin may cleave and inactivate bevacizumab. METHODS: To simulate the intraoperative range of mixing ratios of rtPA, bevacizumab, and subretinal blood, we calculated the volumes of 12 submacular hemorrhages (SHs) with a spherical cap formula using measurements derived from fundus photographs and spectral-domain optical coherence tomographic images. Bevacizumab was incubated with rtPA or plasmin before gel electrophoresis with Coomassie blue and silver staining. The anti-angiogenetic activity of bevacizumab in the presence of rtPA with or without clotted human blood or of plasmin was quantified by vascular endothelial growth factor-enzyme-linked immunosorbent assay after incubation with the supernatant of porcine retinal pigment epithelium cell cultures. RESULTS: The mean (SD) volume of SH was 28.6 (24.7) mm(3 )(range, 6.2-94.6 mm(3)). In sodium dodecyl sulfate-polyacrylamid electrophoresis with Coomassie blue or silver staining, bevacizumab displayed characteristic patterns of protein bands. No additional fragments were detected in co-application of bevacizumab with either rtPA or plasmin. The anti-angiogenetic activity of bevacizumab remained unchanged in co-application with rtPA with or without blood or plasmin. CONCLUSIONS: We demonstrated the absence of cleavage or functional inactivation of bevacizumab by rtPA in an in-vitro model of their intraoperative co-application as a treatment of SH. Clinical relevance In clinical practice, rtPA and bevacizumab can be co-applied as a treatment for neovascular age-related macular degeneration with SH to simultaneously clear SH and reduce choroidal new vessel activity. |
| | |
Authors:
|
Alexa Klettner; Svenja Puls; Felix Treumer; Johann Roider; Jost Hillenkamp |
Related Documents
:
|
1914438 - Ambulatory measurement of nocturnal fluctuations in subcutaneous blood flow rate in the... 2449138 - Occurrence of substance p, vasoactive intestinal peptide, and calcitonin gene-related p... 17490418 - The effect of alpha-lipoic acid on symptoms and skin blood flow in diabetic neuropathy. 4004328 - Glucocorticoid-induced vasoconstriction in canine skin. 8100758 - Stimulated pancreatic exocrine secretion does not require pancreatic hyperemia in rats.... 8771048 - Mechanisms of prion diseases described as long-lasting disorders of the blood-brain bar... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-3-12 |
Journal Detail:
|
Title: Archives of ophthalmology Volume: - ISSN: 1538-3601 ISO Abbreviation: - Publication Date: 2012 Mar |
Date Detail:
|
Created Date: 2012-3-13 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7706534 Medline TA: Arch Ophthalmol Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
University Medical Center Schleswig-Holstein, Campus Kiel, Germany. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Genotype-Phenotype Correlations in Bardet-Biedl Syndrome.
Next Document: Corneal Haze Determined by Confocal Microscopy 2 Years After Descemet Stripping With Endothelial Ker...